All great points Tony. The other point here is that many of the doctors won’t sign on without seeing the efficacy report. They need it for their insurance and to be able to show it to their patients. Longs know the paper was delayed to add the 100 CaverStem 2.0 patients, and I think we are going to see that it will be worth the wait. Over 90% of patient have had a positive impact from CaverStem, and just like the first 40 patients, many of them were problematic patients that did not respond to little blue pills. Nothing is 100%, everyone knows it. It will be miraculous for the every day ED sufferers.
Many don’t like the technical jargon in the paper, or they way it’s written without simple numbers that traders can understand, but the doctors and those who want to see it, see that it simply proves it is safe and that it works.
And that has been clear all along. Anyone who has had blood drawn or gets a flu shot knows you can get a small bruise or be sore. And it’s obviously safe, even to a novice. At the simplest level, it your OWN stem cells. There can’t be a reaction, jeez.
CaverStem will see new doctors signing up at a quicker pace, patients will learn about it at a quicker pace, FemCelz is ready, and the big kid on the block StemSpine is ready too. RS, no RS, or modified again, things will change here soon. Mark it!
AI
Market Data 
Markets 
